Furthermore, if clinical trials confirm discrepancies in response rates for PD-1/PD-L1 checkpoint blockades between primary and recurrent glioblastoma tumours, a panel describing the landscape of molecular characteristics of the TME in both types of glioblastoma patients is worth investigating. This evidence concerns the gene CD274 and neoplasm.